Rifaboly M Tablet combines the potent antibacterial effects of Rifaximin and Metronidazole, offering a dual-action therapy for treating a variety of gastrointestinal and infectious conditions. Rifaximin, a broad-spectrum antibiotic, works by inhibiting bacterial RNA synthesis, effectively targeting certain types of bacteria, particularly those found in the intestines. It is highly effective in treating gastrointestinal infections caused by gram-positive and gram-negative bacteria. Metronidazole, an antiprotozoal and antibiotic agent, targets anaerobic bacteria and protozoa, ensuring a comprehensive approach to infections.
This combination is particularly useful in managing Traveler's Diarrhea, Irritable Bowel Syndrome (IBS) with diarrhea, and intestinal infections caused by susceptible microorganisms. The combination of these two drugs works synergistically to treat infections that may be resistant to one agent alone, providing faster relief and reducing the risk of infection spread.
The dual action of Rifaboly M Tablet helps to control symptoms such as diarrhea, bloating, abdominal discomfort, and cramping while targeting the root cause of the infection. It is also effective in managing conditions like Clostridium difficile infections and giardiasis.